Clinical Trials Browser

Astrocytoma, Ganglioneuroma, Glioblastoma, Glioma, Histiocytosis, Langerhans-Cell, Neuroblastoma, Neurofibromatosis 1, Oligodendroglioma, Ganglioglioma, Neurocytoma, Neurofibroma, Plexiform

NCT07407803 2026-02-12

Evaluation of TQ-B3234 Capsules in Patients With Symptomatic, Non-Surgical Type 1 Neurofibromatosis-Associated Plexiform Neurofibromas

Phase 3 Not yet recruiting

177 enrolled

CNS

Neurofibroma, Plexiform

NCT04590235 2026-01-30

A Study of Selumetinib in Chinese Paediatric and Adult Subjects With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN)

Phase 1 Active not recruiting

32 enrolled

CNS

Neurofibromatosis 1, Neurofibroma, Plexiform

NCT04924608 2026-01-12

KOMET

Phase 3 Active not recruiting

145 enrolled 17 charts 1 FDA

CNS

Neurofibromatosis 1, Neurofibroma, Plexiform

NCT06515860 2026-01-09

NF1-TED

Recruiting

1,000 enrolled

CNSSarcoma

Neurofibromatosis 1, Neurofibroma, Plexiform, Neurofibrosarcoma

NCT02544022 2026-01-08

Development and Validation of Patient Reported Outcome (PRO) Measures for Individuals With Neurofibromatosis 1 (NF1) and Plexiform Neurofibromas (pNFs)

Recruiting

476 enrolled

CNS

Neurofibromatosis 1, Neurofibroma, Plexiform

NCT06961565 2025-12-04

PAS-004 in Adults Who Have Neurofibromatosis Type 1 With Plexiform Neurofibromas

Phase 1 Recruiting

56 enrolled

CNS

Neurofibromatosis 1, Neurofibromatoses, Neurofibroma, Plexiform

NCT06541847 2025-11-21

INSPIRE-NF1

Phase 2 Recruiting

25 enrolled

CNS

Neurofibromatosis 1, Neurofibroma, Plexiform

NCT06222203 2025-09-26

Surveillance for Malignant Transformation of Neurofibromatosis Type 1 (NF1) Related Peripheral Nerve Sheath Tumors (PNST)

Recruiting

225 enrolled

CNSSarcoma

Neurofibroma, Neurofibromatosis 1, Nerve Sheath Neoplasms, Neurofibroma, Plexiform, Neurofibrosarcoma

NCT05238909 2025-09-02

Developing Biomarkers of Plexiform Tumor Burden in Patients With Neurofibromatosis-Type 1

Enrolling by invitation

200 enrolled

CNS

Neurofibroma, Neurofibromatosis 1, Neurofibroma, Plexiform

NCT03962543 2025-08-07

ReNeu

Phase 2 Active not recruiting

114 enrolled 25 charts 1 FDA

CNS

Neurofibroma, Neurofibromatosis 1, Neurofibromatoses, Neurofibroma, Plexiform

NCT07024394 2025-06-17

Follow-up Study to Evaluate the Safety and Efficacy of FCN-159 in Pediatric Participants With Neurofibromatosis Type 1

Phase 1/2 Not yet recruiting

65 enrolled

CNS

Neurofibromatosis 1, Neurofibroma, Plexiform

NCT03231306 2025-05-02

NF108-BINI

Phase 2 Completed

45 enrolled 8 charts

CNS

Neurofibroma, Neurofibromatosis 1, Peripheral Nervous System Neoplasms, Neurofibromatoses, Neurofibroma, Plexiform

NCT05683678 2025-04-04

US Selumetinib Registry

Terminated

37 enrolled

CNS

Neurofibromatosis 1, Neurofibroma, Plexiform

NCT06763315 2025-01-08

LS-NF1PNs

Phase 2 Not yet recruiting

50 enrolled

CNS

Neurofibromatosis 1, Neurofibroma, Plexiform

NCT04954001 2024-11-12

Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and Pediatric Participants With Neurofibromatosis Type 1

Phase 1/2 Active not recruiting

160 enrolled

CNS

Neurofibromatosis 1, Neurofibroma, Plexiform

NCT06379230 2024-04-23

A Retrospective Study on Epidemiological Characteristics of Chinese NF1 Patients in Real World (PROMISE)

Recruiting

2,000 enrolled

CNS

Neurofibromatosis 1, Neurofibroma, Plexiform

NCT03741101 2024-04-11

plexifpc

Phase 2 Active not recruiting

15 enrolled

CNS

Neurofibromatosis 1, Neurofibroma, Plexiform

NCT05028166 2024-03-15

Individual Patient Compassionate Use of Mirdametinib

Available

CNS

Neurofibromatoses, Neurofibroma, Plexiform

NCT05199376 2024-02-09

CryoNF1

Phase NA Recruiting

30 enrolled

CNS

Neurofibroma, Neurofibroma, Plexiform

NCT03363217 2023-11-27

Trametinib for Pediatric Neuro-oncology Patients With Refractory Tumor and Activation of the MAPK/ERK Pathway.

Phase 2 Active not recruiting

114 enrolled

CNS

Brain Neoplasms, Glioma, Neurofibromatosis 1, Neurofibroma, Plexiform

NCT05825365 2023-08-14

PROTECT

Phase 2 Withdrawn

CNS

Neurofibromatosis 1, Neurofibroma, Plexiform

NCT05331105 2023-05-31

HL-085 in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas

Phase 2 Recruiting

70 enrolled

CNS

Neurofibromatosis 1, Neurofibroma, Plexiform

NCT02101736 2023-05-24

NF105-CABO

Phase 2 Completed

45 enrolled 10 charts

CNS

Neurofibromatoses, Neurofibroma, Plexiform

NCT02471339 2022-06-14

Acceptance and Commitment Training for Adolescents and Young Adults With Neurofibromatosis Type 1, Plexiform Neurofibromas, and Chronic Pain

Phase 3 Completed

66 enrolled 17 charts

CNS

Neurofibromatosis 1, Neurofibroma, Plexiform

NCT01800032 2021-05-12

PET/MRI in CNS and Extra-CNS Tumors of Patients With Neurofibromatosis-1 (NF1)

Completed

30 enrolled

CNS

Neurofibroma, Plexiform, Optic Nerve Glioma

NCT03820778 2021-03-02

Whole Body MRI to Identify Atypical Neurofibromas in Patients With NF1

Phase NA Active not recruiting

10 enrolled

CNS

Neurofibromatosis, type 4, of Riccardi, Neurofibroma, Neurofibromatosis 1, Neurofibroma, Plexiform

NCT03688568 2021-02-12

Study of Imatinib in Children With Neurofibromatosis and Airway Tumors

Phase 2 Withdrawn

CNS

Neurofibroma, Plexiform

NCT00006435 2020-05-04

Study of Plexiform Neurofibromas in Neurofibromatosis Type 1

Completed

24 enrolled

CNS

Neurofibroma, Plexiform

NCT03259633 2020-05-01

An Intermediate Access Protocol for Selumetinib for Treatment of Neurofibromatosis Type 1

Approved for marketing

CNS

Neurofibroma, Plexiform

NCT00340522 2019-12-16

Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development

Completed

20 enrolled

CNSSarcoma

Brain Neoplasms, Neoplasms, Neoplasms, Germ Cell and Embryonal, Sarcoma, Neurofibroma, Plexiform

NCT00727233 2019-12-12

Sorafenib to Treat Children and Young Adults With Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibromas

Phase 1 Completed

9 enrolled

CNS

Neurofibromatosis 1, Neurofibroma, Plexiform

NCT02177825 2019-04-08

Study of Imatinib Mesylate in Neurofibromatosis Type I Patients Aged 2 to 21 With Plexiform Neurofibromas

Phase 2 Terminated

5 enrolled

CNS

Neurofibroma, Plexiform

NCT03109301 2019-04-05

Mitogen Activated Protein Kinase Kinase (MEK1/2) Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in People With Neurofibromatosis Type 1 (NF1) Mutated Gastrointestinal Stromal Tumors (GIST)

Phase 2 Withdrawn

CNS

Neoplasms, Nerve Tissue, Neurofibromatosis 1, Peripheral Nervous System Diseases, Neurofibroma, Plexiform, Heredodegenerative Disorders, Nervous System

NCT00076102 2018-04-23